Perlmutter Cancer Center

This study is evaluating safety and feasibility of palbociclib in combination with an established re-induction platform for children, adolescents and young adults with relapsed/refractory ALL and lymphoblastic lymphoma. Targeting cell cycle progression has been an effective therapeutic strategy in a spectrum of malignancies. Prior studies have shown that deregulation of the physiological cell cycle machinery is essential for both the induction and progression of ALL. Additionally, molecular targeting of the interaction of D type cyclins with cell cycle dependent kinases (CDK4 and 6) efficiently suppressed ALL growth and disease progression in vivo and this effect was augmented by concomitant delivery of cytotoxic agents.